Safety and Activity of HF50 in Patients With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of HF50 in Patients With Advanced Solid Tumors
A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is an open-label, dose-escalation and dose-expansion, multiple-dose, phase 1 study evaluating HF50 monotherapy in participants with advanced solid tumors. HF50 is an innovative liposome-encapsulated T-cell engager designed to redirect T-cells to tumor cells by presenting both tumor-associated antigen (e.g., HER2) and CD3 targeting moieties on the liposome surface. Simultaneously, HF50 delivers an encapsulated TLR7/8 agonist to activate innate immunity and remodel the tumor immune microenvironment, creating a synergistic anti-tumor immune response.The primary objective is to evaluate the safety and tolerability of HF50 and to determine the recommended Phase 2 dose (RP2D). HF50 will be administered as an intravenous (IV) infusion. The study will also assess the pharmacokinetic (PK) profile, immunogenicity, and preliminary anti-tumor activity of HF50. Additionally, the study will explore the impact of HF50 on the immune microenvironment and changes in peripheral blood cytokines and immune cells to better understand its biological effects.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: xun Wang
- Numero di telefono: +86-571-86961869
- Email: wangxun717416@gmail.com
Luoghi di studio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100021
- Non ancora reclutamento
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contatto:
- FEI MA, MD,PhD
-
Investigatore principale:
- FEI MA, MD,PhD
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510120
- Reclutamento
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Investigatore principale:
- Jing Li, MD, PhD
-
Investigatore principale:
- Qiong Yang, MD, PhD
-
Contatto:
- HERUI YAO, MD,PhD
- Numero di telefono: +8613500018020
- Email: yaohrsysu@163.com
-
Investigatore principale:
- HERUI YAO, MD,PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Voluntary participation: Capable of giving signed informed consent and able to comply with all study-related procedures.
- Age: Adults >= 18 years of age at the time of signing informed consent; male or female.
- Disease Status: Participants with histologically or cytologically confirmed advanced solid tumors that are unresectable or metastatic, who have failed or are intolerant to standard therapies, or for whom no effective therapy currently exists. Examples include HER2-expressing gynecological tumors and recurrent ovarian clear cell carcinoma after failure of platinum-based chemotherapy.
- Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- Life Expectancy: Anticipated survival of no less than 6 months.
- Measurable Disease: At least one measurable lesion according to RECIST v1.1 definitions.
- Organ and Bone Marrow Function:
Bone Marrow Reserve: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, lymphocyte count >= 1.0 x 10^9/L, platelet count >= 90 x 10^9/L, and hemoglobin >= 9.0 g/dL (no blood transfusion or hematopoietic stimulators within 14 days).
Coagulation Function: Activated partial thromboplastin time (APTT) <= 1.5 x ULN, and International Normalized Ratio (INR) <= 1.5.
Liver Function: Total bilirubin (TBIL) <= 1.5 x ULN, and ALT and AST <= 2.5 x ULN. For participants with liver metastases: ALT and AST <= 5 x ULN, and TBIL <= 3 x ULN.
Renal Function: Creatinine clearance >= 50 mL/min (calculated using the Cockcroft-Gault formula).
- Contraception: Participants of reproductive potential (including males) must agree to use effective contraception from study entry through 6 months after the last dose. Female participants of childbearing potential must have a negative serum pregnancy test during screening and prior to the first dose.
Exclusion Criteria:
- Autoimmune Disease: Any active autoimmune disease or history of autoimmune disease deemed unsuitable by the investigator. Exceptions include skin conditions not requiring systemic treatment (e.g., eczema < 10% of body surface area, vitiligo, psoriasis, alopecia) and resolved childhood asthma.
- Corticosteroids/Immunosuppressants: Current use of immunosuppressants or systemic corticosteroids (> 10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose. Topical steroid use is permitted.
- Prior Anti-tumor Therapy: Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 2 weeks prior to dosing (4 weeks for nitrosoureas or mitomycin C); or other therapies (endocrine therapy, TCM, localized palliative radiotherapy) within 2 weeks.
- CNS Metastasis: Clinically symptomatic brain or meningeal metastases. Participants with treated brain metastases are eligible if radiographic stability is maintained for >= 28 days, systemic steroids have been discontinued for > 14 days, and the participant is asymptomatic.
- Toxicity Recovery: Failure to recover from all adverse events of prior therapies to <= Grade 1 (NCI CTCAE v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement.
- Cardiovascular History: Including thromboembolic events within 3 months; NYHA Class III to IV congestive heart failure; acute coronary syndrome, aortic dissection, stroke, or other Grade >= 3 cardiovascular events within 6 months; or uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg).
- Infection: Active infection or unexplained fever > 38.5 degrees C within 1 week prior to the first dose (tumor-related fever is permitted per investigator judgment).
- Viral Infection: HIV infection, active HBV (HBV DNA > ULN), or active HCV (HCV RNA > ULN).
- Gastrointestinal Symptoms: Significant digestive system symptoms or other factors requiring intervention within 4 weeks prior to the first dose.
- Pregnancy/Lactation: Female participants who are pregnant or breastfeeding.
- Other: Any other serious systemic disease or reason that, in the investigator's opinion, makes the participant unsuitable for the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: HF50
HF50 monotherapy |
HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants with Dose Limiting Toxicities (DLT)
Lasso di tempo: 28 days after the first dose (C1D1) for each dose cohort.
|
The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD). |
28 days after the first dose (C1D1) for each dose cohort.
|
|
Incidence of Adverse Events (AEs)
Lasso di tempo: From first dose to 28 days after the last dose.
|
The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0 |
From first dose to 28 days after the last dose.
|
|
Recommended Phase II Dose (RP2D) of HF50
Lasso di tempo: At the end of dose escalation (assessed up to 1 year)
|
RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase. |
At the end of dose escalation (assessed up to 1 year)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate (ORR)
Lasso di tempo: Up to 2 years
|
Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria. |
Up to 2 years
|
|
Duration of Response (DOR)
Lasso di tempo: Up to 2 years
|
Time from the first documented response (CR or PR) to disease progression or death. |
Up to 2 years
|
|
Disease Control Rate (DCR)
Lasso di tempo: Up to 2 years
|
Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1. |
Up to 2 years
|
|
Progression-Free Survival (PFS)
Lasso di tempo: Up to 2 years
|
Time from the first dose to disease progression or death. |
Up to 2 years
|
|
Overall Survival (OS)
Lasso di tempo: Up to 2 years
|
Time from the first dose to death from any cause. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Cmax
Lasso di tempo: Up to 2 years
|
Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Tmax
Lasso di tempo: Up to 2 years
|
Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing. |
Up to 2 years
|
|
Pharmacokinetic Parameter - AUC (Area Under the Curve)
Lasso di tempo: Up to 2 years
|
AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50. |
Up to 2 years
|
|
Pharmacokinetic Parameter - Half-life (t1/2)
Lasso di tempo: Up to 2 years
|
The terminal elimination half-life (t1/2) of HF50 will be calculated. |
Up to 2 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: HERUI YAO, MD,PhD, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HF50-102
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .